With the International Classification of Diseases, Tenth Revision, definitely being implemented on October 1, 2015, CMS just completed the first week of end-to-end testing of the new coding.
With the International Classification of Diseases, Tenth Revision (ICD-10), definitely being implemented on October 1, 2015, CMS just completed the first week of end-to-end testing of the new coding.
More than 600 providers and billing companies submitted nearly 15,000 test claims during the first week of ICD-10 testing. ICD-10 codes are more specific than the current ICD-9, which will allow for better understanding about a patient’s health, according to CMS.
According to statistics released by CMS, 81% of the test claims received were accepted. While 3% of claims were rejected due to invalid submission of ICD-9 diagnosis or procedure code and another 3% from invalid submission of ICD-10 diagnosis or procedure code, the majority of rejected claims were for reasons unrelated to ICD-10.
“Overall, participants in the January 26 to February 3 testing were able to successfully submit ICD-10 claims and have them processed through our billing systems,” CMS Administrator Marilyn Tavenner wrote in a blog post. “To the extent that some claims were rejected, most didn’t meet the mark because of errors unrelated to ICD-9 or ICD-10.”
ICD-10 implementation has been fraught with challenges. Preparedness for ICD-10 has varied greatly across the industry with providers showing the least progress in the last year, according to a survey from the Workgroup for Electronic Data Interchange.
The initial round of end-to-end testing was supposed to take place in May 2014, just 5 months before what was then an October 1, 2014, implementation deadline. However, after a Congressional mandate delayed ICD-10 by at least 1 year, CMS canceled testing all together last year.
The United States is the last industrialized nation to adopt ICD-10, and the World Health Organization will release the ICD-11 code set, at the earliest, in 2017. Since ICD-10 is a foundational building block, it must be implemented before the US can move onto ICD-11.
Any services that are provided on or after October 1 will need to use ICD-10, but any services provided before October 1, even if the codes are not submitted until after that date, will need to use ICD-9. Prior to October 1, ICD-10 can only be used for testing purposes.
And Ms Tavenner strongly recommended in her blog post that medical practices and hospitals take advantage of ICD-10 testing opportunities to ensure they will be prepared for the transition date.
“I appreciate the tremendous efforts and achievements of health professionals as we work together to realize the benefits of ICD-10 and other advances toward the ultimate goal of improving the quality and affordability of health care for all Americans,” she wrote.
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health
April 18th 2025Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.
Read More
Understanding How Fitness Affects Digestive Diseases
April 18th 2025Exercise is a powerful modulator of gut health in patients with gastrointestinal (GI) conditions, as moderate activity can ease gut inflammation, reduce colorectal cancer risk, and relieve constipation, while intense workouts may backfire, causing reflux, GI bleeding, or gut barrier disruption.
Read More
FDA Greenlights Dupilumab for Chronic Spontaneous Urticaria, Marking First Approval in a Decade
April 18th 2025Marking the first approval in over a decade for this challenging condition, the FDA has approved dupilumab (Dupixent) to treat chronic spontaneous urticaria in patients 12 years and older whose hives and itching remain uncontrolled by antihistamines.
Read More